CL2021003442A1 - Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer. - Google Patents

Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.

Info

Publication number
CL2021003442A1
CL2021003442A1 CL2021003442A CL2021003442A CL2021003442A1 CL 2021003442 A1 CL2021003442 A1 CL 2021003442A1 CL 2021003442 A CL2021003442 A CL 2021003442A CL 2021003442 A CL2021003442 A CL 2021003442A CL 2021003442 A1 CL2021003442 A1 CL 2021003442A1
Authority
CL
Chile
Prior art keywords
defactinib
methods
pharmaceutical composition
idelalisib
treating cancer
Prior art date
Application number
CL2021003442A
Other languages
English (en)
Inventor
Nidhi Singh
Meenakshi Venkatasubramanian
Quinn Jackson
Original Assignee
Pattern Computer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pattern Computer Inc filed Critical Pattern Computer Inc
Publication of CL2021003442A1 publication Critical patent/CL2021003442A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE IDELALISIB Y DEFACTINIB; Y MÉTODOS PARA EL TRATAMIENTO DE CÁNCER.
CL2021003442A 2019-06-21 2021-12-21 Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer. CL2021003442A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962864870P 2019-06-21 2019-06-21
US202063031749P 2020-05-29 2020-05-29

Publications (1)

Publication Number Publication Date
CL2021003442A1 true CL2021003442A1 (es) 2022-10-07

Family

ID=74037382

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2021003442A CL2021003442A1 (es) 2019-06-21 2021-12-21 Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
CL2023003090A CL2023003090A1 (es) 2019-06-21 2023-10-17 Combinaciones de composiciones terapéuticas y usos para tratar cánceres

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2023003090A CL2023003090A1 (es) 2019-06-21 2023-10-17 Combinaciones de composiciones terapéuticas y usos para tratar cánceres

Country Status (8)

Country Link
US (1) US20220354874A1 (es)
EP (1) EP3999065A4 (es)
CN (1) CN114401723B (es)
AU (1) AU2020297587A1 (es)
CA (1) CA3144639A1 (es)
CL (2) CL2021003442A1 (es)
MX (1) MX2022000082A (es)
WO (1) WO2020257615A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115192717B (zh) * 2021-04-08 2023-12-12 海创药业股份有限公司 一种治疗癌症的药物组合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015054099A1 (en) * 2013-10-08 2015-04-16 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and either her2 inhibitors or pi3k inhibitors
EP3102232B1 (en) * 2014-02-07 2020-02-05 Verastem, Inc. Methods and compositions for treating abnormal cell growth
WO2015161285A1 (en) * 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in the protection of hematopoietic stem and progenitor cells against ionizing radiation
WO2016130546A1 (en) * 2015-02-10 2016-08-18 Memorial Sloan Kettering Cancer Center Dye-stabilized nanoparticles and methods of their manufacture and therapeutic use
EP3313443B9 (en) * 2015-06-25 2023-10-04 Immunomedics, Inc. Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
JP2018525425A (ja) * 2015-08-28 2018-09-06 ノバルティス アーゲー がんを治療または予防するためのリボシクリブとダブラフェニブの組み合わせ
WO2017201043A1 (en) * 2016-05-16 2017-11-23 Concert Pharmaceuticals, Inc. Combination therapy for treating cancer
CA3032813A1 (en) * 2016-08-04 2018-02-08 Gilead Sciences, Inc. Cobicistat for use in cancer treatments
EP3496754A4 (en) * 2016-08-11 2020-04-15 Immunomedics, Inc. EFFECTIVENESS OF ANTI-HLA-DR ANTIBODY DRUG CONJUGATE IN? -140 (HL243-CL2A-SN-38) IN HLA-DR POSITIVE CANCER DISEASES
US20180141939A1 (en) * 2016-11-22 2018-05-24 Gilead Sciences, Inc. Solid forms of a bet inhibitor
WO2018122168A1 (en) * 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors

Also Published As

Publication number Publication date
US20220354874A1 (en) 2022-11-10
CA3144639A1 (en) 2020-12-24
EP3999065A4 (en) 2023-09-13
CN114401723A (zh) 2022-04-26
CN114401723B (zh) 2024-11-08
WO2020257615A1 (en) 2020-12-24
EP3999065A1 (en) 2022-05-25
AU2020297587A1 (en) 2022-02-03
CL2023003090A1 (es) 2024-03-08
MX2022000082A (es) 2022-06-16

Similar Documents

Publication Publication Date Title
CL2021000084A1 (es) Inhibidores de pd-1/pd-l1
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CL2019000979A1 (es) Composiciones y anticuerpos anti-lag-3.
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
CL2018001358A1 (es) Composiciones que comprenden cepas bacterianas
CL2023003068A1 (es) Compuestos, composiciones y métodos para el tratamiento de trastornos
CL2017002494A1 (es) Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
BR112017023517A2 (pt) anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
BR112018008882A8 (pt) método para tratar um distúrbio proliferativo e produto farmacêutico
CL2019002427A1 (es) Inhibición de smarca2 para el tratamiento de cáncer.
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
BR112019024566A2 (pt) inibidores de pirazol magl
BR112022008365A2 (pt) Inibidores de cd73
PH12017501879A1 (en) Methods for treating cancer
CL2020002624A1 (es) Formulaciones de inmunoconjugado anti-cd79b estables.
BR112019002458A2 (pt) composições e métodos para tratar câncer com depleção de arginina e agentes imuno-oncológicos
BR112019003533A2 (pt) terapia de combinação com inibidores de glutaminase
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
CL2023000892A1 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional).
CL2022000967A1 (es) Composiciones y métodos para el tratamiento de enfermedades hepáticas
UY38352A (es) Inhibidores de integrina alfavbeta6
BR112018068027A2 (pt) método para tratar câncer em um paciente e composição farmacêutica
CO2021007006A2 (es) Moduladores de la expresión de irf5